Skip to main content
SpringerLink
Log in

Mannigfaltige Therapieoptionen — was hilft wirklich?

Migräne — Therapie im Wandel

Migraine — therapy in transition

  • FORTBILDUNG . ÜBERSICHT
  • Published:
MMW - Fortschritte der Medizin Aims and scope

An Erratum to this article was published on 12 July 2019

Zusammenfassung

Die Migräne ist die häufigste neurologische Erkrankung, die mit einer erheblichen Beeinträchtigung der Lebensqualität der Betroffenen, aber auch mit gesundheitsökonomischen Konsequenzen einhergeht. Damit es gar nicht erst zum Migräneanfall kommt, haben prophylaktische Maßnahmen einen hohen Stellenwert. Und besonders auf diesem Gebiet hat sich nun etwas getan.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Olesen J. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, Asbtracts. Cephalalgia. 2018;38:1–211

    Google Scholar 

  2. Lipton RB et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68:343–9

    Article  CAS  Google Scholar 

  3. Saylor D, Steiner TJ. The global burden of headache. Seminars in neurology, 2018. Thieme Medical Publishers

  4. Steiner TJ et al. The impact of headache in Europe: principal results of the Eurolight project. The journal of headache and pain. 2014;15:31

    Article  Google Scholar 

  5. Stovner LJ et al. Global, regional, and national burden of migraine and tension-type headache. 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology. 2018;17:954–76

    Article  Google Scholar 

  6. Kahriman, A. and S. Zhu. Migraine and Tension-Type Headache. Seminars in neurology, 2018. Thieme Medical Publishers.

  7. Dodick DW. A Phase-by-Phase Review of Migraine Pathophysiology. Headache: The Journal of Head and Face Pain. 2018;58:4–16

    Article  Google Scholar 

  8. Charles A. The evolution of a migraine attack—a review of recent evidence. Headache: The Journal of Head and Face Pain. 2013;3:413–9

    Article  Google Scholar 

  9. Charles A. The pathophysiology of migraine: implications for clinical management. The Lancet Neurology. 2018;17:174–82

    Article  CAS  Google Scholar 

  10. Giffin N et al. Premonitory symptoms in migraine: an electronic diary study. Neurology. 2003;60:935–40

    Article  CAS  Google Scholar 

  11. Goadsby PJ et al. Pathophysiology of migraine: a disorder of sensory processing. Physiological reviews. 2017;97:553–622

    Article  Google Scholar 

  12. Kissoon NR, and Cutrer FM. Aura and Other Neurologic Dysfunction in or with Migraine. Headache. 2017;57:1179–94

    Article  Google Scholar 

  13. Cutrer FM, Huerter K. Migraine aura. The neurologist. 2007;13:118–25

    Article  Google Scholar 

  14. Kelman L. Pain characteristics of the acute migraine attack. Headache: The Journal of Head and Face Pain. 2006;46:942–53

    Article  Google Scholar 

  15. Giffin NJ et al. The migraine postdrome: an electronic diary study. Neurology. 2016;87:309–13

    Article  Google Scholar 

  16. Antonaci F et al. Recent advances in migraine therapy. Springerplus. 2016;5:637

    Article  Google Scholar 

  17. Cameron C et al. Triptans in the acute treatment of migraine: a systematic review and network meta-analysis. Headache: The Journal of Head and Face Pain. 2015;55:221–35

    Article  Google Scholar 

  18. Long BJ, Koyfman A. Benign headache management in the emergency department. The Journal of emergency medicine. 2018;54:458–68

    Article  Google Scholar 

  19. Minen MT, Tanev K, Friedman BW. Evaluation and treatment of migraine in the emergency department: a review. Headache: The Journal of Head and Face Pain, 2014;54:1131–45

    Article  Google Scholar 

  20. Rozen TD. Emergency department and inpatient management of status migrainosus and intractable headache. Continuum: Lifelong Learning in Neurology. 2015;21:1004–17

    PubMed  Google Scholar 

  21. Viana M et al. Triptan nonresponders: Do they exist and who are they? Cephalalgia. 2013;33:891–6

    Article  Google Scholar 

  22. Holland PR, Goadsby PJ. Targeted CGRP small molecule antagonists for acute migraine therapy. Neurotherapeutics. 2018;2:304–12

    Article  Google Scholar 

  23. Kuca B et al. Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study. Neurology. 2018:91:e2222–32

    Article  CAS  Google Scholar 

  24. Martelletti P, Giamberardino MA. Advances in orally administered pharmacotherapy for the treatment of migraine. Expert opinion on pharmacotherapy. 2019;20:209–18

    Article  CAS  Google Scholar 

  25. Oswald JC, Schuster NM. Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice. Journal of pain research.2018;11:2221

    Article  Google Scholar 

  26. Tfelt-Hansen P, Loder E. The Emperor's New Gepants: Are the Effects of the New Oral CGRP Antagonists Clinically Meaningful? Headache: The Journal of Head and Face Pain. 2019;59:113–7

    Article  Google Scholar 

  27. Raffaelli B et al. The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraine. Expert opinion on pharmacotherapy. 2017;18:1409–15

    Article  CAS  Google Scholar 

  28. Lambru G et al. Emerging drugs for migraine treatment: an update. Expert opinion on emerging drugs. 2018;23:301–18

    Article  CAS  Google Scholar 

  29. Edvinsson L. CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment. British journal of clinical pharmacology. 2015;80:193–9

    Article  CAS  Google Scholar 

  30. Voss T et al. A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia. 2016;36:887–98

    Article  Google Scholar 

  31. Marcus R et al. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia. 2014;34:114–25

    Article  Google Scholar 

  32. Kropp P et al. Entspannungsverfahren und verhaltenstherapeutische Interventionen zur Behandlung der Migräne. Der Schmerz. 2017;31:433–47

    Article  CAS  Google Scholar 

  33. Diener H-C, Gaul C, Kropp P et al. Therapie der Migräneattacke und Prophylaxe der Migräne. S1-Leitlinie, 2018; in: Deutsche Gesellschaft für Neurologie (Hrsg.), Leitlinien für Diagnostik und Therapie in der Neurologie. Online: www.dgn.org/leitlinien (abgerufen am 06.06.2019)

  34. Sprenger T, Viana M, Tassorelli C. Current Prophylactic Medications for Migraine and Their Potential Mechanisms of Action. Neurotherapeutics. 2018;15:313–23

    Article  CAS  Google Scholar 

  35. Rohling S et al. Integrated headache care at the outpatient headache center of the University Hospital of Munich: The Munich model. Clinical and Translational Neuroscience. 218; https://doi.org/10.1177/2514183X18786844

    Article  Google Scholar 

  36. Blumenfeld AM et al. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: Results from the Second International Burden of Migraine Study (IBMS-II). Headache: The Journal of Head and Face Pain. 2013;53:644–55

    Article  Google Scholar 

  37. Loder E, Rizzoli P. Pharmacologic prevention of migraine: a narrative review of the state of the art in 2018. Headache: The Journal of Head and Face Pain. 2018;58:218–29

    Article  Google Scholar 

  38. Stubberud A et al. Flunarizine as prophylaxis for episodic migraine: a systematic review with meta-analysis. Pain. 2019;160:762–72

    Article  CAS  Google Scholar 

  39. Bagnato F, Good J. The use of antiepileptics in migraine prophylaxis. Headache: The Journal of Head and Face Pain. 2016;56:603–15

    Article  Google Scholar 

  40. Couch JR, A.V.P.S. Group. Amitriptyline in the prophylactic treatment of migraine and chronic daily headache. Headache: The Journal of Head and Face Pain. 2011;51:33–51

    Article  Google Scholar 

  41. Eftekhari S et al. Localization of CGRP, CGRP receptor, PACAP and glutamate in trigeminal ganglion. Relation to the blood-brain barrier. Brain research. 2015;1600:93–109

    Article  CAS  Google Scholar 

  42. Paemeleire K, and MaassenVanDenBrink A. Calcitonin-gene-related peptide pathway mAbs and migraine prevention. Current opinion in neurology. 2018;31:274–80

    CAS  PubMed  Google Scholar 

  43. Dodick DW et al. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38:1026–37

    Article  Google Scholar 

  44. Goadsby PJ et al. A controlled trial of erenumab for episodic migraine. New England Journal of Medicine. 2017;377):2123–32

    Article  CAS  Google Scholar 

  45. Sun H et al. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Neurology. 2016; 15:382–90

    Article  CAS  Google Scholar 

  46. Tepper S et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. The Lancet Neurology. 2017;16:425–34

    Article  CAS  Google Scholar 

  47. Dodick DW et al. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. The Lancet Neurology. 2014;13:885–92

    Article  CAS  Google Scholar 

  48. Skljarevski V et al. Effect of different doses of galcanezumab vs placebo for episodic migraine prevention: a randomized clinical trial. JAMA neurology. 2018;75:187–93

    Article  Google Scholar 

  49. Skljarevski V et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38:1442–54

    Article  Google Scholar 

  50. Stauffer VL et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA neurology. 2018;75:1080–8

    Article  Google Scholar 

  51. Bigal ME et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. The Lancet Neurology. 2015;14):1081–90

    Article  CAS  Google Scholar 

  52. Bigal ME et al. TEV-48125 for the preventive treatment of chronic migraine: efficacy at early time points. Neurology. 2016;87:41–8

    Article  CAS  Google Scholar 

  53. Silberstein SD et al. Fremanezumab for the preventive treatment of chronic migraine. New England Journal of Medicine. 2017; 377:2113–22

    Article  CAS  Google Scholar 

  54. Tepper SJ. Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Update on a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018. Headache: The Journal of Head and Face Pain. 2018;58:276–90

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neurologische Klinik und Poliklinik, Klinikum der Universität München, LMU München, Marchioninistraße 15, D-81377, München, Deutschland

    Katharina Kamm &  Andreas Straube

  2. Klinik für Neurologie mit Experimenteller Neurologie, Charité Universitätsmedizin Berlin, Berlin, Deutschland

    Lars Neeb

Authors
  1. Katharina Kamm
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andreas Straube
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lars Neeb
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katharina Kamm.

Additional information

Interessenkonflikt

Die Autoren erklären, dass sie sich bei der Erstellung des Beitrages von keinen wirtschaftlichen Interessen leiten ließen. Sie legen folgende potenzielle Interessenkonflikte offen: Vortrags- und Beratungstätigkeiten für Pharm Allergan, Novartis, TEVA, Lilly, Boehringer Ingelheim, Sanofi, electroCore sowie Teilnahme an Studien für die Firmen Novartis, TEVA, Lilly und electroCore (Prof. Straube). Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kamm, K., Straube, A. & Neeb, L. Migräne — Therapie im Wandel. MMW - Fortschritte der Medizin 161, 50–58 (2019). https://doi.org/10.1007/s15006-019-0021-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-019-0021-y

Keywords

Search

Navigation